Phase 3 Double-blind Multicenter Randomized Active-Controlled Study to Evaluate the Safety and Efficacy of Bictegravir/Lenacapavir Versus Biktarvy® (Bictegravir/Emtricitabine/Tenofovir Alafenamide) in Virologically Suppressed People With HIV-1

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 31 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bictegravir (Primary) ; Emtricitabine (Primary) ; Lenacapavir (Primary) ; Tenofovir (Primary)
Indications HIV-1 infections
Focus Registrational; Therapeutic Use
Acronyms ARTISTRY-2
Sponsors Gilead Sciences

Most Recent Events

27 Dec 2024 Status changed from recruiting to active, no longer recruiting.
25 Jul 2024 Results presented in the Gilead Sciences Media Release
24 Jul 2024 According to a Gilead Sciences media release, data from the study were presented at the 25th International AIDS Conference (AIDS 2024).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight